Literature DB >> 28992528

Adjuvant therapy in renal cell carcinoma.

Francesco Massari1, Vincenzo Di Nunno2, Chiara Ciccarese3, Jeffrey Graham4, Camillo Porta5, Francesca Comito2, Marta Cubelli2, Roberto Iacovelli3, Daniel Y C Heng4.   

Abstract

Several drugs have demonstrated clinical activity in metastatic renal cell carcinoma (mRCC). The identification of key metabolic pathways has led to the development of novel targeted therapies which have drastically changed the treatment paradigm of mRCC. Moreover, immune-checkpoint inhibitors have recently shown significant activity in advanced disease. Despite these advancements, the role of adjuvant therapy in localized, non-metastatic RCC remains unclear. The utility of many of these agents in the adjuvant setting is currently being actively explored. In this review, we will summarize the main clinical trials investigating adjuvant therapy in renal cell carcinoma, focusing primarily on immunotherapy and targeted agents.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adjuvant treatment; Clear cell renal cell carcinoma; Immunotherapy; Renal cell carcinoma; Tyrosine kinases inhibitors

Mesh：

Substances：

Year:  2017        PMID： 28992528     DOI： 10.1016/j.ctrv.2017.09.004

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


  8 in total

1.  miR-625-3p promotes migration and invasion and reduces apoptosis of clear cell renal cell carcinoma.

Authors:  Liwen Zhao; Kaihao Liu; Xiang Pan; Jing Quan; Liang Zhou; Zuwei Li; Canbin Lin; Jinling Xu; Weijie Xu; Xin Guan; Hang Li; Liangchao Ni; Yaoting Gui; Yongqing Lai
Journal:  Am J Transl Res       Date:  2019-10-15       Impact factor: 4.060

Review 2.  Functions of circular RNAs in bladder, prostate and renal cell cancer (Review).

Authors:  Longfei Yang; Xiaofeng Zou; Junrong Zou; Guoxi Zhang
Journal:  Mol Med Rep       Date:  2021-03-02       Impact factor: 2.952

Review 3.  Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution.

Authors:  Veronica Mollica; Vincenzo Di Nunno; Lidia Gatto; Matteo Santoni; Alessia Cimadamore; Liang Cheng; Antonio Lopez-Beltran; Rodolfo Montironi; Salvatore Pisconti; Nicola Battelli; Francesco Massari
Journal:  Clin Drug Investig       Date:  2019-06       Impact factor: 3.580

Review 4.  Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time.

Authors:  Wouter W van Willigen; Martine Bloemendal; Winald R Gerritsen; Gerty Schreibelt; I Jolanda M de Vries; Kalijn F Bol
Journal:  Front Immunol       Date:  2018-10-01       Impact factor: 7.561

5.  MicroRNA-372 functions as a tumor suppressor in cell invasion, migration and epithelial-mesenchymal transition by targeting ATAD2 in renal cell carcinoma.

Authors:  Shiqi Ji; Xiaolin Su; Haijian Zhang; Zhixing Han; Yuqian Zhao; Qingjun Liu
Journal:  Oncol Lett       Date:  2018-12-28       Impact factor: 2.967

6.  FSIP2 can serve as a predictive biomarker for Clear Cell Renal Cell Carcinoma prognosis.

Authors:  Yixiao Zhang; Xudong Zhu; Xinbo Qiao; Lisha Sun; Ye Tian; Yongliang Yang; Yuhong Zhao; Caigang Liu
Journal:  Int J Med Sci       Date:  2020-10-08       Impact factor: 3.738

7.  Immunotherapy in renal cell carcinoma: latest evidence and clinical implications.

Authors:  Matteo Santoni; Francesco Massari; Vincenzo Di Nunno; Alessandro Conti; Alessia Cimadamore; Marina Scarpelli; Rodolfo Montironi; Liang Cheng; Nicola Battelli; Antonio Lopez-Beltran
Journal:  Drugs Context       Date:  2018-06-05

8.  Identification of an individualized autophagy prognostic index in clear cell renal cell carcinoma patients.

Authors:  Yi Jin; Feng Li; Peiyuan Guo; Keqin Dong; Peng Guo; Haoyuan Wang; Yujia Chen; Zhiyu Wang
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.